Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity.

David K Wallace,Amra Hercinovic,Sharon F Freedman,Eric R Crouch,Amit R Bhatt,M Elizabeth Hartnett,Michael B Yang,David L Rogers,Amy K Hutchinson,William V Good,Michael X Repka,Zhuokai Li,Roy W Beck,Raymond T Kraker,Susan A Cotter,Jonathan M Holmes

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus（2023）

引用 5|浏览19

暂无评分

摘要

In this study cohort, there was no statistically significant correlation between dosage of bevacizumab and Bayley scores at 2 years. However, the sample size was small and the retention rate relatively low, limiting our conclusions. Rates of high myopia and ocular abnormalities do not differ from those reported after larger bevacizumab doses.

查看译文

关键词

retinopathy,bevacizumab,prematurity,developmental outcomes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要